Chronic Hypoxemia Inadvanced Liver Diseases: Hepatopulmonary Syndrome

Article Sidebar

PDF
Published: Sep 5, 2023
DOI: https://doi.org/10.47191/ijmscrs/v3-i9-04
Keywords:
Hepatopulmonary syndrome chronic dyspnea chronic liver diseases chronic hypoxemia

Main Article Content

I Putu Eka Krisnha Wijaya
Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta, Indonesia

Abstract

Hepatopulmonary syndrome (HPS) is one of the pulmonary complications from liver disease with or without cirrhosis. The prevalence of HPS varies from 4% to 47% in patients with liver cirrhosis. We present a case of chronic progressive dyspnea in an 18-year-old man with a history of chronic liver disease. Diagnosing can be particularly challenging, especially in cases involving prolonged dyspnea and comorbidities. Following thorough investigations, the patient's condition was attributed to a rarer condition: severe hepatopulmonary syndrome. Contrast-enhanced echocardiography with agitated saline is the gold standard for diagnosing pulmonary vascular dilatation which is the hallmark of HPS. There is currently no medical therapy approved for HPS. Oxygen therapy is recommended for patients with severe hypoxemia.

Article Details

How to Cite
Wijaya, I. P. E. K. (2023). Chronic Hypoxemia Inadvanced Liver Diseases: Hepatopulmonary Syndrome. International Journal of Medical Science and Clinical Research Studies, 3(9), 1817–1821. https://doi.org/10.47191/ijmscrs/v3-i9-04
Issue
Vol. 3 No. 9 (2023): Volume 03 Issue 09 September 2023
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

I. Grace JA, Angus PW. Hepatopulmonary syndrome: update on recent advances in pathophysiology, investigation, and treatment. J Gastroenterol Hepatol. 2013;28(2):213-9.

II. Soulaidopoulos S, Cholongitas E, Giannakoulas G, Vlachou M, Goulis I. Review article: Update on current and emergent data on hepatopulmonary syndrome. World J Gastroenterol. 2018;24(12):1285-98.

III. Zhang J, Fallon MB. Hepatopulmonary syndrome: update on pathogenesis and clinical features. Nat Rev Gastroenterol Hepatol. 2012;9(9):539-49.

IV. Schenk P, Schöniger-Hekele M, Fuhrmann V, et al. Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology. 2003;125(4):1042-52.

V. Nacif LS, Andraus W, Pinheiro RS, et al. The hepatopulmonary syndrome. Arq Bras Cir Dig. 2014;27(2):145-7.

VI. Raevens S, Boret M, Fallon MB. Hepatopulmonary syndrome. JHEP Rep. 2022;4(9):100527.

VII. Thenappan T, Goel A, Marsboom G, et al. A central role for CD68(+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion. Am J Respir Crit Care Med. 2011;183(8):1080-91.

VIII. Bansal K, Gore M, Mittal S. Hepatopulmonary syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562169/

IX. Varghese J, Ilias-basha H, Dhanasekaran R, et al. Hepatopulmonary syndrome - past to present. Ann Hepatol. 2007;6(3):135-42.

X. Regev A, Yeshurun M, Rodriguez M, et al. Transient hepatopulmonary syndrome in a patient with acute hepatitis A. J Viral Hepat. 2001;8(1):83-6.